ASND · earnings call history
Ascendis Pharma Q2 FY26 — Strong TransCon Product Uptake and Pipeline Advancement
Read the briefAscendis Pharma Q1 FY26 — Strong Revenue Growth and YUVIWEL Launch
Read the briefBrowse all US companies on the earnings-call register.